|
|
||||||||
Ann Thorac Surg 2004;78:1352-1361
© 2004 The Society of Thoracic Surgeons
a Division of Pediatric Cardiac Surgery, New York, New York, USA
b Division of Pediatric Cardiology, New York, New York, USA
c Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, New York, USA
Accepted for publication April 1, 2004.
* Address reprint requests to Dr Chen, Pediatric Cardiac Surgery, Childrens Hospital of New York, 3959 Broadway, Suite 2-273, New York, NY 10032, USA
jmc23{at}columbia.edu
Presented at the Fortieth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 2628, 2004.
| Abstract |
|---|
|
|
|---|
METHODS: A retrospective review was performed to evaluate all patients undergoing cardiac transplantation from January 1, 1984 through January 1, 2004. Donor and recipient demographic and intraoperative and postoperative variables were acquired and correlated with perioperative (30-day) and late mortality in both univariate and multivariate analyses, and with Kaplan-Meier survival estimates.
RESULTS: One hundred and six patients underwent transplantation for complex congenital heart disease and were followed for a median of 56 months. Thirty-seven (34.9%) patients died. Male gender and later year of transplantation were protective, and neonatal age and pulmonary artery reconstruction detrimental in multivariable modeling of overall mortality. Transplantation to a physiologic or anatomic single lung did not impact on survival. Patients in the study cohort had comparable survival estimates when compared with all those in the entire cohort without complex congenital heart disease. When comparing patients by era of transplantation, both cohorts demonstrated improved survival with later transplantation.
CONCLUSIONS: Outcomes with transplantation for complex congenital heart disease have improved annually over the past twenty years. Transplantation to an anatomic or physiologic single lung did not impair overall survival. Pulmonary artery reconstruction imparted an increase in mortality both short and long term, a finding which merits further investigation.
| Introduction |
|---|
|
|
|---|
| Material and Methods |
|---|
|
|
|---|
Hospital chart review was conducted on each identified patient and their donor, and the data entered into a computerized database. Donor and recipient demographic and intraoperative and postoperative variables were acquired (Appendix). For the purposes of analysis, date of transplant was considered separately, both as a continuous variable as well as in three subgroups ("eras"); 1980 to 1989, 1990 to 1999, 2000 to 2003. This study received approval for exemption from the Institutional Review Board of Columbia University.
Statistical methods
Univariate and multivariate statistical methods were used to identify and estimate risk factors for all-cause mortality, as well as 30-day perioperative mortality in this population. In addition the study population was compared, using similar methods, to the cohort of all other patients undergoing cardiac transplantation at our institution. The methods of statistical analysis included:
2 test for comparisons of dichotomous risk factors with negative outcomes, Mantel-Haenszel
2 test for comparisons taking into consideration disease severity, and the Wilcoxon test for comparisons of continuous variables with negative outcomes (p < 0.05). Logistic regression analysis of the cumulative incidence was used to evaluate the influence of risk factors for mortality. Life-table estimates (Kaplan-Meier) were calculated using the LIFETEST procedure of SAS 6.12 for PowerPC (SAS Institute, Cary, NC) with the log-rank test for difference between strata.
Following univariate analysis, variables were entered into multivariate models (using the LOGISTIC procedure) in a forward stepwise manner in the following order: gender, pulmonary artery reconstruction, prior shunt, tetralogy of Fallot, single ventricle physiology, pulmonary atresia, year of transplant, and age. Age and year of transplantation were entered as both continuous and categorized variables; no significant differences between these analyses were noted.
Cox proportional hazards regression models (using the PHREG procedure [SAS Institute]) were constructed in the same manner in order to identify those variables most predictive of improved survival functions. Threshold for entry into the model for both logistic regression and Cox regression was p less than 0.05.
| Results |
|---|
|
|
|---|
2 analysis of patients grouped by age, and analyzed by era, demonstrated increased mortality with younger age (p = 0.044), particularly in the early era (p = 0.021). Cardiopulmonary bypass time, aortic cross-clamp time, and donor heart ischemic times were mean (range), respectively: 228 (83 to 557) minutes; 135 (53 to 301) minutes; and 237 (68 to 443) minutes. These times notably were not significantly correlated with mortality, or with any pulmonary artery reconstruction. Four patients required deep hypothermic circulatory arrest to complete their transplant for an average time of 44.8 minutes (range, 18 to 80 minutes). Primary anatomic diagnoses are represented in Table 2. Donor-recipient height and weight mismatch did not predict early or late mortality.
|
|
|
Neither serum albumin nor serum total protein was directly associated with anatomic diagnosis, or perioperative mortality. Serum albumin levels preoperatively, 6 months postoperatively, and late postoperatively were, respectively, mean, median (range): 3.8, 3.9 (2 to 5.8); 4.5, 4.5 (2.1 to 5.9); 4.2, 4.3 (2.0 to 5.3). Only late postoperative serum albumin was significantly associated with all cause mortality (p = 0.03), suggesting the poor physiologic condition of those patients who died.
Thirty-seven (34.9%) patients died; their causes of death are represented in Table 3. Results of the univariate analysis of overall mortality are represented in Figure 2. A similar analysis of predictors of perioperative (30-day) mortality was performed. Only neonates were at higher risk of perioperative death (odds ratio 7.467, 95% confidence interval (CI) 1.5116 to 36.783), p = 0.005). Univariate analysis of continuous variables predictive of overall mortality demonstrated only earlier year of transplant to be predictive of overall mortality (p = 0.0002).
|
|
|
|
|
|
Seven patients required mechanical assistance preoperatively, four patients needed mechanical assistance perioperatively, and two patients required assistance late postoperatively; Table 6 summarizes these cohorts. As demonstrated, patients were bridged on average 5.3 days (median 6 days; range, 1 day to 10 days) before transplantation with a variety of devices. All three mortalities were in the immediate postoperative period, and all three involved a component of intractable hemorrhage. There was a trend toward increased perioperative (risk ratio 2.891, 95% CI 0.794 to 19.073, p = 0.075) and overall (risk ratio 1.434, 95% CI 0.303 to 6.778, p = 0.648) mortality in these patients. One of the patients required extracorporeal membrane oxygenation (ECMO) support after transplantation for primary graft failure and was retransplanted 8 days later, and one required ECMO after transplantation for primary nonfunction and was decannulated two days later. Two adult patients who were placed on intraoperative right ventricular assist device (RVAD) support (for primary nonfunction and right ventricular failure) died intraoperatively. Both patients had undergone significant pulmonary artery reconstruction: the first patient had undergone transplantation after two failed Fontan operations; her pulmonary artery confluence had been reconstructed with a 12 mm Dacron graft to which the donor pulmonary artery was anastomosed. The second patient had undergone bilateral modified and classic Blalock-Taussig shunts, and had also had a classic Glenn procedure and required a transplant to her right lung only. The first patient was unable to wean from cardiopulmonary bypass despite right RVAD support; the second died ultimately of a combination of hemorrhage and pulmonary edema. Two patients required ECMO late posttransplant for progressive respiratory decompensation in the setting of adult respiratory distress syndrome (ARDS) and sepsis.
|
| Comment |
|---|
|
|
|---|
The success of cardiac transplantation as a therapy for patients with single ventricle physiology has prompted some investigators to endorse its application as a primary therapy for these diagnoses, most notably for hypoplastic left heart syndrome [9]. Indeed, while the results of this approach at certain centers have been remarkably good, the application of this strategy nationwide would be epidemiologically impractical, given the limited number of neonatal and infant donors. In contrast, others have proposed staged palliation and other means to defer transplantation until the patient reaches adolescence, citing better donor organ availability and results in this setting [10]. Our results demonstrated several findings in the complex congenital cohort with regard to age: (1) neonates tended to have poorer outcomes, most notably in the earliest era of transplantation, and (2) patients in older age groups demonstrated a trend toward survival advantage in the univariate analysis of overall mortality. However, among all patients transplanted, infants and children regardless of their type of congenital heart disease demonstrated a survival advantage in the multivariable domain. It is likely that some of the inconsistencies of these findings may be due to small sample size, variance of follow-up with respect to age, and nature and limits of the given statistical test. We hope such discrepancies will be elucidated better with a larger cohort.
More recently, improved long-term outcomes with staged procedures toward ultimate Fontan completion have approached those of transplantation, achieving in many cases comparable survival without the burden of lifelong immunosuppression regimen. Nonetheless, as higher risk patients are considered for staged repair, and as these patients age, a growing subset of patients fail these protocols, thereby comprising a group who present for transplantation after a variety of prior palliative procedures.
In this setting, some have advocated early consideration for heart transplantation before high-risk Fontan, so as to help eliminate the reported increased mortality for "rescue" transplantation [11, 12]. We did not find the stage of the procedure per se to confer a statistically significant change in outcome; however, this may be due to the relatively low numbers considered. We also did not find, as has been previously described, an increase in mortality attributable to reconstruction of systemic or pulmonary venous return when coupled with transplantation [1, 13].
Our data are notable for several key observations. First, although stage of the procedure (for those single ventricle patients) was not specifically associated with a difference in mortality, both a prior shunt procedure and pulmonary artery reconstruction demonstrated impairment in perioperative and long-term survival. These two characteristics demonstrated substantial overlap. However, pulmonary artery reconstruction demonstrated the strongest association with mortality (odds ratio 3.3) in regression models that best fit the data set. In an effort to better understand this association, the cohort was further segregated on the basis of degree of reconstruction, and this demonstrated an incremental risk of perioperative mortality from mild to moderate to extensive reconstruction (15.2%, 23.1%, 42.9% 30-day mortality, respectively); this was not true of overall mortality (36.4%, 53.9%, 42.9%). When considered as a group, patients with any pulmonary artery reconstruction demonstrated a strong trend toward impaired survival (p = 0.051) throughout the follow-up period when compared by Kaplan-Meier actuarial analysis.
Our explanations for this phenomenon are only speculative. While it is conceivable that this cohort may have occult pulmonary parenchymal lung disease from longstanding arterial shunts, it remains difficult to associate fully this with all-cause mortality. This concept is supported by the finding of an increase in transpulmonary gradient on preoperative catheterization in those patients undergoing pulmonary artery reconstruction who died. In many congenital heart transplant candidates, and in particular in this cohort of patients with prior pulmonary artery anatomic abnormalities (eg, prior shunt, discontinuous pulmonary arteries, pulmonic stenosis, and atresia), preoperative pulmonary artery pressures and calculated indices of pulmonary vascular resistance can be both difficult to assess and misleading. Investigation of posttransplant pulmonary indices did not demonstrate findings to account for this difference. As investigators from our institution have previously asserted, in this setting the essential problem is achieving an acceptable pulmonary vascular resistance after transplantation [8].
Second, and relatedly, we found that in those twelve patients who underwent transplantation to a single lung, perioperative mortality was comparable to those who underwent no pulmonary artery reconstruction. We are increasingly referred such patients in whom one pulmonary artery was iatrogenically (eg, prior shunt) or naturally atretic or discontinuous. In those with true anatomic variance, we have chosen to baffle the donor pulmonary artery toward the functional side. In others, in whom the difference is more physiologic (eg, longstanding pulmonary venous obstruction), the reconstruction is routine, although the flow is unquestionably preferential [14]. Four of these patients died. One patient died intraoperatively, despite RVAD support, one patient died on postoperative day 6 during a pulmonary hypertensive crisis, one patient died one month postoperatively of ARDS and multiorgan failure, and one patient died 3 years later of chronic rejection. We have been pleasantly surprised by the relatively good outcome of this group, and have learned that aggressive pulmonary toilet and avoidance of events that may precipitate pulmonary hypertensive crises are essential.
Third, the survival benefit afforded male patients in the overall cohort was magnified in the group with complex congenital heart disease. We have previously demonstrated this finding in our overall cohort, and additional investigators have speculated that, in adult patients, multiparity, immunologic reactivity, and gender and size mismatch may account for poorer long-term outcomes (and organ availability) for women [1517]. However, this does not seem a likely explanation in children. While the overall cohort itself demonstrates a slight male predominance, it is not enough to account for this difference, which remains unexplained.
Fourth, neonatal patients tended to have a higher mortality than all others, especially in the early era (before 1990). Certainly, over the past twenty years, the overall perioperative management of neonates has improved, and this is reflected in our data as well. While this cohort is limited in number, it is notable that three of the four deaths involved pulmonary hemorrhage, likely due in part to lung prematurity.
Fifth, our outcomes with the use of mechanical assistance as a bridge-to-transplantation and for posttransplant support have been variable. Certainly with the likely advent of newer, smaller devices for mechanical ventricular assistance, VAD support in this cohort may become more prevalent. All of the deaths in the cohort bridged with ECMO relate to bleeding complications, undoubtedly due partially to the requirement of systemic anticoagulation for the duration of pretransplant support. We have used ECMO occasionally posttransplant for early graft insufficiency in other congenital heart disease patients, and its low prevalence in this cohort is likely due to sample bias. One patient who did require ECMO for primary graft failure was successfully retransplanted 8 days later; the other was weaned from ECMO and decannulated after 48 hours of support. Although anecdotal, it would appear from our experience that unilateral RVAD support is not recommended for this group of patients, many of whom have pulmonary resistances that, when coupled with supraphysiologic right sided (ie, device) output, may produce pulmonary edema and early mortality. In these patients, complete right sided decompression with ECMO may be better tolerated.
Sixth, year of transplantation remains a strong predictor of mortality in both univariate and multivariable modeling. Indeed, when considered as a continuous variable in the Cox regression analysis, the effect on overall mortality was such that for each more recent year of transplantation, mortality decreased by approximately 11%. Advances in surgical techniques, preservation protocols, perioperative adjuncts, immunosuppression regimen, and long-term management all contribute to this improvement. Although the association between year of experience and improved survival was evident in both study and control cohorts (Fig 4), this relationship was stronger in those with complex congenital heart disease (Tables 4 and 5).
Finally, the survival estimates of our patients transplanted with and without complex congenital heart disease were comparable (Fig 3). While there was a significant difference in mortality demonstrated in the perioperative period by univariate and multivariable analysis, the long-term survival of this cohort was comparable to all others without complex congenital heart disease. Several investigators have described a similar phenomenon when considering all patients with congenital heart disease (including those with isolated cardiomyopathy); however, we demonstrate this to be true in cases that otherwise might be considered "high-risk." In addition, adults in our cohort (who comprise an increasingly larger subgroup at our program) demonstrated excellent overall survival, a finding in keeping with our previous reports, as well as the reports of others with regard to heart, heart-lung, and lung transplantation in this setting [18, 19].
We report encouraging results regarding transplantation for complex congenital heart disease in children and adults. Future advances in the selection and management of patients who may require substantial pulmonary artery reconstruction may help to better define the association with short-term and long-term mortality. However, transplantation to an anatomic or physiologic single lung should not in itself be a contraindication to transplantation. We hope that the future availability of ventricular assist devices of appropriate sizes for children may help bridge more patients in this cohort to transplantation, and that their appropriate implementation might reduce wait list mortality, and that advances in the treatment of transplant coronary artery disease may meaningfully impact on long-term survival.
Limitations
Several limitations must be highlighted in the current study. First, by its nature, this evaluation is subject to the restrictions of a retrospective study. Second, pretransplant information on patients transplanted in the early era was inconsistently available. Third, the value of preoperative calculated pulmonary hemodynamic indices remains complicated, in particular for those in whom a significant discrepancy was present between branch pulmonary arteries. Future studies will hopefully better elucidate nuances in patient selection to better define mortality risk stratification among patients in this cohort.
| Appendix |
|---|
|
DISCUSSION
DR THOMAS SPRAY (Philadelphia, PA): I think this is an excellent series and certainly the outcomes are to be commended. It is interesting that almost all of the difference in mortality between the various eras is early postoperative mortality. This would suggest that were getting better at reconstructing these patients.
If thats the case, then, the other thing that strikes me is that the cross-clamp times, or overall operative times, seem to be similar in the congenital group and the adult group. Now, is that reflecting the fact that your adult population is skewed largely now towards patients who have had multiple reoperations and ventricular assist device implants and, therefore, the total time of operation is similar? One would assume that in the congenital as well?
DR CHEN: Thank you, Dr Spray, for your comments. We did in fact analyze ischemic times, cross-clamp times and overall OR times throughout the study period, and I was also surprised to find that the congenital group was comparable to all others. Some of this, as you point out, is due to the fact that our noncongenital adult population is similarly comprised of complex patients who have had many prior operations and LVADs, etc., and part of it is likely due to the fact that we have improved the coordination of our transplants.
Not infrequently, we may delay cross-clamp at the donor hospital until we are sure that we are "out of the woods" in the recipient case, so as not to prolong the ischemic time unnecessarily. This, I suspect, may be the reason that there was not a correlation between complexity of the PA reconstruction and overall ischemic time.
All of which, however, is not to detract from your conclusion that we are getting better at reconstructing these patientsId like to think that this is true as well.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. M. Lamour, K. R. Kanter, D. C. Naftel, M. R. Chrisant, W. R. Morrow, B. S. Clemson, J. K. Kirklin, and CTRD (Cardiac Transplant Registry Database) and th The Effect of Age, Diagnosis, and Previous Surgery in Children and Adults Undergoing Heart Transplantation for Congenital Heart Disease. J. Am. Coll. Cardiol., July 7, 2009; 54(2): 160 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
M M Winter, B J Bouma, M Groenink, T C Konings, J G P Tijssen, D J van Veldhuisen, and B J M Mulder Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failure Heart, June 15, 2009; 95(12): 960 - 963. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Davies, M. J. Russo, S. Mital, T. M. Martens, R. S. Sorabella, K. N. Hong, A. C. Gelijns, A. J. Moskowitz, J. M. Quaegebeur, R. S. Mosca, et al. Predicting survival among high-risk pediatric cardiac transplant recipients: An analysis of the United Network for Organ Sharing database J. Thorac. Cardiovasc. Surg., January 1, 2008; 135(1): 147 - 155. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L.S. Morales, W. J. Dreyer, S. W. Denfield, J. S. Heinle, E. D. McKenzie, D. E. Graves, J. F. Price, J. A. Towbin, O.H. Frazier, D. A. Cooley, et al. Over two decades of pediatric heart transplantation: How has survival changed? J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 632 - 639. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Canter, R. E. Shaddy, D. Bernstein, D. T. Hsu, M. R.K. Chrisant, J. K. Kirklin, K. R. Kanter, R. S.D. Higgins, E. D. Blume, D. N. Rosenthal, et al. Indications for Heart Transplantation in Pediatric Heart Disease: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group Circulation, February 6, 2007; 115(5): 658 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Raisky, D. Tamisier, and P. R. Vouhe Orthotopic heart transplantation for congenital heart defects: anomalies of the systemic venous return MMCTS, October 9, 2006; 2006(1009): 1578. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-R. Hosseinpour, S. Cullen, and V. T. Tsang Transplantation for adults with congenital heart disease. Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 508 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Graham Jr The Year in Congenital Heart Disease J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1887 - 1899. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |